• Citing Article List

    The journal uses Crossref Cited-by service counts times cited of published articles. Cited-by allows Crossref members to find out who is citing their content. This is the Citing Article List of “Current strategies for the design of PROTAC linkers: a critical review”.
    No. Publication Date Citing Article
    1 2023 Ester Colarusso, Sara Ceccacci, Maria Chiara Monti, Erica Gazzillo, Assunta Giordano, Maria Giovanna Chini, Maria Grazia Ferraro, Marialuisa Piccolo, Dafne Ruggiero, Carlo Irace, Stefania Terracciano, Ines Bruno, Giuseppe Bifulco, Gianluigi Lauro. Identification of 2,4,5-trisubstituted-2,4-dihydro-3H-1,2,4-triazol-3-one-based small molecules as selective BRD9 binders, European Journal of Medicinal Chemistry. 2023; 247: 115018115018.  https://doi.org/10.1016/j.ejmech.2022.115018
    2 2022 Federica Pedrucci, Claudia Pappalardo, Giovanni Marzaro, Nicola Ferri, Alberto Ferlin, Luca De Toni. Proteolysis Targeting Chimeric Molecules: Tuning Molecular Strategies for a Clinically Sound Listening, International Journal of Molecular Sciences. 2022; 23: 6630.  https://doi.org/10.3390/ijms23126630
    3 2022 Markus Fleck, Michael Müller, Noah Weber, Christopher Trummer. Decoupled coordinates for machine learning-based molecular fragment linking, Machine Learning: Science and Technology. 2022; 3: 015029.  https://doi.org/10.1088/2632-2153/ac50fc
    4 2023 Friedericke S. Menke, Barbara Wicher, Lars Allmendinger, Victor Maurizot, Ivan Huc. An abiotic, tetrameric, eight-helix bundle, Chemical Science. 2023; 14: 3742.  https://doi.org/10.1039/D3SC00267E
    5 2022 Diego García Jiménez, Matteo Rossi Sebastiano, Maura Vallaro, Valentina Mileo, Daniela Pizzirani, Elisa Moretti, Giuseppe Ermondi, Giulia Caron. Designing Soluble PROTACs: Strategies and Preliminary Guidelines, Journal of Medicinal Chemistry. 2022; 65: 12639.  https://doi.org/10.1021/acs.jmedchem.2c00201
    6 2022 Jenny Desantis, Andrea Mammoli, Michela Eleuteri, Alice Coletti, Federico Croci, Antonio Macchiarulo, Laura Goracci. PROTACs bearing piperazine-containing linkers: what effect on their protonation state?, RSC Advances. 2022; 12: 21968.  https://doi.org/10.1039/D2RA03761K
    7 2023 Weijun Gui, Sarah F. Giardina, Madeline Balzarini, Francis Barany, Thomas Kodadek. Reversible Assembly of Proteolysis Targeting Chimeras, ACS Chemical Biology. 2023; 18: 1582.  https://doi.org/10.1021/acschembio.3c00199
    8 2022 Jiacheng Li, Ting Liu, Yuanli Song, Mingyu Wang, Liping Liu, Hongwen Zhu, Qi Li, Jin Lin, Hualiang Jiang, Kaixian Chen, Kehao Zhao, Mingliang Wang, Hu Zhou, Hua Lin, Cheng Luo. Discovery of Small-Molecule Degraders of the CDK9-Cyclin T1 Complex for Targeting Transcriptional Addiction in Prostate Cancer, Journal of Medicinal Chemistry. 2022; 65: 11034.  https://doi.org/10.1021/acs.jmedchem.2c00257
    9 2023 Li Zhou, Bin Yu, Mengqiu Gao, Rui Chen, Zhiyu Li, Yueqing Gu, Jinlei Bian, Yi Ma. DNA framework-engineered chimeras platform enables selectively targeted protein degradation, Nature Communications. 2023; 14: 4510.  https://doi.org/10.1038/s41467-023-40244-7
    10 2023 Huda Zahid, Jeff P. Costello, Yao Li, Jennifer R. Kimbrough, Marisa Actis, Zoran Rankovic, Qin Yan, William C. K. Pomerantz. Design of Class I/IV Bromodomain-Targeting Degraders for Chromatin Remodeling Complexes, ACS Chemical Biology. 2023; 18: 1278.  https://doi.org/10.1021/acschembio.2c00902
    11 2023 Yu-Ling Tseng, Po-Chao Lu, Chi-Chang Lee, Ruei-Yu He, Yung-An Huang, Yin-Chen Tseng, Ting-Jen Rachel Cheng, Joseph Jen-Tse Huang, Jim-Min Fang. Degradation of neurodegenerative disease-associated TDP-43 aggregates and oligomers via a proteolysis-targeting chimera, Journal of Biomedical Science. 2023; 30: 27.  https://doi.org/10.1186/s12929-023-00921-7
    12 2022 Jiadai Zhai, Chuang Li, Bingxia Sun, Sinan Wang, Yuting Cui, Qingzhi Gao, Feng Sang. Sunitinib-based Proteolysis Targeting Chimeras (PROTACs) reduced the protein levels of FLT-3 and c-KIT in leukemia cell lines, Bioorganic & Medicinal Chemistry Letters. 2022; 78: 129041129041.  https://doi.org/10.1016/j.bmcl.2022.129041
    13 2021 Martin Reynders, Dirk Trauner. Optical control of targeted protein degradation, Cell Chemical Biology. 2021; 28: 969.  https://doi.org/10.1016/j.chembiol.2021.05.010
    14 2022 Irene Preet Bhela, Alice Ranza, Federica Carolina Balestrero, Marta Serafini, Silvio Aprile, Rita Maria Concetta Di Martino, Fabrizio Condorelli, Tracey Pirali. A Versatile and Sustainable Multicomponent Platform for the Synthesis of Protein Degraders: Proof-of-Concept Application to BRD4-Degrading PROTACs, Journal of Medicinal Chemistry. 2022; 65: 15282.  https://doi.org/10.1021/acs.jmedchem.2c01218
    15 2022 Vasanthanathan Poongavanam, Yoseph Atilaw, Stephan Siegel, Anja Giese, Lutz Lehmann, Daniel Meibom, Mate Erdelyi, Jan Kihlberg. Linker-Dependent Folding Rationalizes PROTAC Cell Permeability, Journal of Medicinal Chemistry. 2022; 65: 13029.  https://doi.org/10.1021/acs.jmedchem.2c00877
    16 2023 Arjun Rao, Tin M. Tunjic, Michael Brunsteiner, Michael Müller, Hosein Fooladi, Chiara Gasbarri, Noah Weber. Bayesian optimization for ternary complex prediction (BOTCP), Artificial Intelligence in the Life Sciences. 2023; 3: 100072100072.  https://doi.org/10.1016/j.ailsci.2023.100072
    17 2023 Giulia Apprato, Giulia D’Agostini, Paolo Rossetti, Giuseppe Ermondi, Giulia Caron. In Silico Tools to Extract the Drug Design Information Content of Degradation Data: The Case of PROTACs Targeting the Androgen Receptor, Molecules. 2023; 28: 1206.  https://doi.org/10.3390/molecules28031206
    18 2022 Izidor Sosič, Aleša Bricelj, Christian Steinebach. E3 ligase ligand chemistries: from building blocks to protein degraders, Chemical Society Reviews. 2022; 51: 3487.  https://doi.org/10.1039/D2CS00148A
    19 2022 O. A. Koroleva, Yu. V. Dutikova, A. V. Trubnikov, F. A. Zenov, E. V. Manasova, A. A. Shtil, A. V. Kurkin. PROTAC: targeted drug strategy. Principles and limitations, Russian Chemical Bulletin. 2022; 71: 2310.  https://doi.org/10.1007/s11172-022-3659-z
    20 2022 Tatsuya Sawasaki, Satoshi Yamanaka, Hirotake Furihata, Yuuki Imai, Yuta Yanagihara, Koya Nagaoka, Yuki Shoya, Shuhei Yoshida, Norio Shibata, Akihito Taya, Takato Nagasaka, Mai Usui, Hidetaka Kosako, Kohei Nishino, Takuya Miyakawa, Masaru Tanokura. 2022;   https://doi.org/10.21203/rs.3.rs-2173987/v1
    21 2021 Aleša Bricelj, Yuen Lam Dora Ng, Dominic Ferber, Robert Kuchta, Sina Müller, Marius Monschke, Karl G. Wagner, Jan Krönke, Izidor Sosič, Michael Gütschow, Christian Steinebach. Influence of Linker Attachment Points on the Stability and Neosubstrate Degradation of Cereblon Ligands, ACS Medicinal Chemistry Letters. 2021; 12: 1733.  https://doi.org/10.1021/acsmedchemlett.1c00368
    22 2022 Zi Liu, Mingxing Hu, Yu Yang, Chenghao Du, Haoxuan Zhou, Chengyali Liu, Yuanwei Chen, Lei Fan, Hongqun Ma, Youling Gong, Yongmei Xie. An overview of PROTACs: a promising drug discovery paradigm, Molecular Biomedicine. 2022; 3: 46.  https://doi.org/10.1186/s43556-022-00112-0
    23 2021 Fanwang Meng, Zhongjie Liang, Kehao Zhao, Cheng Luo. Drug design targeting active posttranslational modification protein isoforms, Medicinal Research Reviews. 2021; 41: 1701.  https://doi.org/10.1002/med.21774
    24 2022 Zubair Anwar, Muhammad Shahzad Ali, Antonio Galvano, Alessandro Perez, Maria La Mantia, Ihtisham Bukhari, Bartlomiej Swiatczak. PROTACs: The Future of Leukemia Therapeutics, Frontiers in Cell and Developmental Biology. 2022; 10: 851087.  https://doi.org/10.3389/fcell.2022.851087
    25 2022 Cheng-Liang Zhu, Xiaomin Luo, Tian Tian, Zijian Rao, Hanlin Wang, Zhesheng Zhou, Zizheng Gao, Tian Mi, Danni Chen, Yongjin Xu, Yizhe Wu, Jinxin Che, Peihua Luo, Yubo Zhou, Jia Li, Xiaowu Dong. Structure-Based Rational Design Enables Discovery of a New Selective and Potent Akt Degrader with Improved Dermatologic Safety, SSRN Electronic Journal . 2022;   https://doi.org/10.2139/ssrn.4056755
    26 2023 Liam Thomas Hales, Philip Evan Thompson. Solid‐Phase Synthesis of PROTACs and SNIPERs on Backbone Amide Linked (BAL) Resin, Chemistry – A European Journal. 2023; e202301975.  https://doi.org/10.1002/chem.202301975
    27 2023 Mingyu Wang, Rongkun Lin, Jiacheng Li, Yuying Suo, Jing Gao, Liping Liu, Liyuan Zhou, Yicheng Ni, Ziqun Yang, Jie Zheng, Jin Lin, Hu Zhou, Cheng Luo, Hua Lin. Discovery of LL-K8-22: A Selective, Durable, and Small-Molecule Degrader of the CDK8-Cyclin C Complex, Journal of Medicinal Chemistry. 2023; 66: 4932.  https://doi.org/10.1021/acs.jmedchem.2c02045
    28 2022 Jyotsana Madan, Vijay Kamal Ahuja, Kamal Dua, Susanta Samajdar, Murali Ramchandra, Sanjeev Giri. PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras, BioDrugs. 2022; 36: 609.  https://doi.org/10.1007/s40259-022-00551-9
    29 2022 Miklós Békés, David R. Langley, Craig M. Crews. PROTAC targeted protein degraders: the past is prologue, Nature Reviews Drug Discovery. 2022; 21: 181.  https://doi.org/10.1038/s41573-021-00371-6
    30 2023 Robert J. Tokarski, Chia M. Sharpe, Andrew C. Huntsman, Brittney K. Mize, Oluwatosin R. Ayinde, Emily H. Stahl, James R. Lerma, Andrew Reed, Bridget Carmichael, Natarajan Muthusamy, John C. Byrd, James R. Fuchs. Bifunctional degraders of cyclin dependent kinase 9 (CDK9): Probing the relationship between linker length, properties, and selective protein degradation, European Journal of Medicinal Chemistry. 2023; 254: 115342115342.  https://doi.org/10.1016/j.ejmech.2023.115342
    31 2022 Guangyan Du, Jie Jiang, Nathaniel J. Henning, Nozhat Safaee, Eriko Koide, Radosław P. Nowak, Katherine A. Donovan, Hojong Yoon, Inchul You, Hong Yue, Nicholas A. Eleuteri, Zhixiang He, Zhengnian Li, Hubert T. Huang, Jianwei Che, Behnam Nabet, Tinghu Zhang, Eric S. Fischer, Nathanael S. Gray. Exploring the target scope of KEAP1 E3 ligase-based PROTACs, Cell Chemical Biology. 2022; 29: 1470.  https://doi.org/10.1016/j.chembiol.2022.08.003
    32 2022 Olga Bakulina, Alexander Sapegin, Alexander S. Bunev, Mikhail Krasavin. Synthetic approaches to constructing proteolysis targeting chimeras (PROTACs), Mendeleev Communications. 2022; 32: 419.  https://doi.org/10.1016/j.mencom.2022.07.001
    33 2021 Olga D. Jarosińska, Stefan G. D. Rüdiger. Molecular Strategies to Target Protein Aggregation in Huntington’s Disease, Frontiers in Molecular Biosciences. 2021; 8: 769184.  https://doi.org/10.3389/fmolb.2021.769184
    34 2022 Arvind Negi, Anne Sophie Voisin‐Chiret. Strategies to Reduce the On‐Target Platelet Toxicity of Bcl‐xL Inhibitors: PROTACs, SNIPERs and Prodrug‐Based Approaches, ChemBioChem. 2022; 23: e202100689.  https://doi.org/10.1002/cbic.202100689
    35 2023 Tin M. Tunjic, Noah Weber, Michael Brunsteiner. Computer aided drug design in the development of proteolysis targeting chimeras, Computational and Structural Biotechnology Journal. 2023; 21: 2058.  https://doi.org/10.1016/j.csbj.2023.02.042
    36 2022 Bohan Ma, Yizeng Fan, Dize Zhang, Yi Wei, Yanlin Jian, Donghua Liu, Zixi Wang, Yang Gao, Jian Ma, Yule Chen, Shan Xu, Lei Li. De Novo Design of an Androgen Receptor DNA Binding Domain‐Targeted peptide PROTAC for Prostate Cancer Therapy, Advanced Science. 2022; 9: 2201859.  https://doi.org/10.1002/advs.202201859
    37 2023 Yi-Qian Li, William G. Lannigan, Shabnam Davoodi, Fereidoon Daryaee, Ana Corrionero, Patricia Alfonso, Jose A. Rodriguez-Santamaria, Nan Wang, John D. Haley, Peter J. Tonge. Discovery of Novel Bruton’s Tyrosine Kinase PROTACs with Enhanced Selectivity and Cellular Efficacy, Journal of Medicinal Chemistry. 2023; 66: 7454.  https://doi.org/10.1021/acs.jmedchem.3c00176
    38 2022 Chaoguo Cao, Ming He, Liguo Wang, Yuna He, Yu Rao. Chemistries of bifunctional PROTAC degraders, Chemical Society Reviews. 2022; 51: 7066.  https://doi.org/10.1039/D2CS00220E
    39 2022 Lakshmi R. Bollu, Prashant V. Bommi, Paige J. Monsen, Lijie Zhai, Kristen L. Lauing, April Bell, Miri Kim, Erik Ladomersky, Xinyu Yang, Leonidas C. Platanias, Daniela E. Matei, Marcelo G. Bonini, Hidayatullah G. Munshi, Rintaro Hashizume, Jennifer D. Wu, Bin Zhang, Charles David James, Peiwen Chen, Masha Kocherginsky, Craig Horbinski, Michael D. Cameron, Arabela A. Grigorescu, Bakhtiar Yamini, Rimas V. Lukas, Gary E. Schiltz, Derek A. Wainwright. Identification and Characterization of a Novel Indoleamine 2,3-Dioxygenase 1 Protein Degrader for Glioblastoma, Journal of Medicinal Chemistry. 2022; 65: 15642.  https://doi.org/10.1021/acs.jmedchem.2c00771
    40 2021 Giuseppe Ermondi, Diego Garcia-Jimenez, Giulia Caron. PROTACs and Building Blocks: The 2D Chemical Space in Very Early Drug Discovery, Molecules. 2021; 26: 672.  https://doi.org/10.3390/molecules26030672
    41 2022 Hanqiao Xu, Takashi Kurohara, Reina Takano, Hidetomo Yokoo, Norihito Shibata, Nobumichi Ohoka, Takao Inoue, Mikihiko Naito, Yosuke Demizu. Development of Rapid and Facile Solid‐Phase Synthesis of PROTACs via a Variety of Binding Styles, ChemistryOpen. 2022; 11: e202200131.  https://doi.org/10.1002/open.202200131
    42 2023 Oluwatosin R. Ayinde, Chia Sharpe, Emily Stahl, Robert J. Tokarski, James R. Lerma, Natarajan Muthusamy, John C. Byrd, James R. Fuchs. Examination of the Impact of Triazole Position within Linkers on Solubility and Lipophilicity of a CDK9 Degrader Series, ACS Medicinal Chemistry Letters. 2023; 14: 936.  https://doi.org/10.1021/acsmedchemlett.3c00082
    43 2021 Yingxin Lu, Danwen Sun, Donghuai Xiao, Yingying Shao, Mingbo Su, Yubo Zhou, Jia Li, Shulei Zhu, Wei Lu. Design, Synthesis, and Biological Evaluation of HDAC Degraders with CRBN E3 Ligase Ligands, Molecules. 2021; 26: 7241.  https://doi.org/10.3390/molecules26237241
    44 2023 Martin P. Schwalm, Andreas Krämer, Anja Dölle, Janik Weckesser, Xufen Yu, Jian Jin, Krishna Saxena, Stefan Knapp. 2023;   https://doi.org/10.1101/2023.01.11.523589
    45 2023 Xiao Cheng, Shiqi Hu, Ke Cheng. Microneedle Patch Delivery of PROTACs for Anti-Cancer Therapy, ACS Nano. 2023; 17: 11855.  https://doi.org/10.1021/acsnano.3c03166
    46 2022 Robert S. Foti, 2022; 716.  https://doi.org/10.1016/B978-0-12-820472-6.00141-9
    47 2023 Madeline Balzarini, Weijun Gui, Isuru M. Jayalath, Bin-Bin Schell, Joel Tong, Thomas Kodadek. 2023;   https://doi.org/10.1101/2023.07.19.549534
    48 2021 M. Maneiro, E. De Vita, D. Conole, C.S. Kounde, Q. Zhang, E.W. Tate. 2021; 60: 67.  https://doi.org/10.1016/bs.pmch.2021.01.002
    49 2023 Atsunori Kaneshige, Longchuan Bai, Mi Wang, Donna McEachern, Jennifer L. Meagher, Renqi Xu, Paul D. Kirchhoff, Bo Wen, Duxin Sun, Jeanne A. Stuckey, Shaomeng Wang. Discovery of a Potent and Selective STAT5 PROTAC Degrader with Strong Antitumor Activity In Vivo in Acute Myeloid Leukemia, Journal of Medicinal Chemistry. 2023; 66: 2717.  https://doi.org/10.1021/acs.jmedchem.2c01665
    50 2023 Nobuo Cho, Mikihiko Naito. 2023; 681: 41.  https://doi.org/10.1016/bs.mie.2022.09.001
    51 2023 Huanghao Mai, Matthew H. Zimmer, Thomas F. Miller. Exploring PROTAC Cooperativity with Coarse-Grained Alchemical Methods, The Journal of Physical Chemistry B. 2023; 127: 446.  https://doi.org/10.1021/acs.jpcb.2c05795
    52 2023 Chien-Ting Kao, Chieh-Te Lin, Cheng-Li Chou, Chu-Chung Lin. Fragment Linker Prediction Using the Deep Encoder-Decoder Network for PROTACs Drug Design, Journal of Chemical Information and Modeling. 2023; 63: 2918.  https://doi.org/10.1021/acs.jcim.2c01287
    53 2022 Cheng-Liang Zhu, Xiaomin Luo, Tian Tian, Zijian Rao, Hanlin Wang, Zhesheng Zhou, Tian Mi, Danni Chen, Yongjin Xu, Yizhe Wu, Jinxin Che, Yubo Zhou, Jia Li, Xiaowu Dong. Structure-based rational design enables efficient discovery of a new selective and potent AKT PROTAC degrader, European Journal of Medicinal Chemistry. 2022; 238: 114459114459.  https://doi.org/10.1016/j.ejmech.2022.114459
    54 2021 Hannah Kiely-Collins, Georg E. Winter, Gonçalo J.L. Bernardes. The role of reversible and irreversible covalent chemistry in targeted protein degradation, Cell Chemical Biology. 2021; 28: 952.  https://doi.org/10.1016/j.chembiol.2021.03.005
    55 2022 Ruth Nussinov, Mingzhen Zhang, Ryan Maloney, Yonglan Liu, Chung-Jung Tsai, Hyunbum Jang. Allostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs, Journal of Molecular Biology. 2022; 434: 167569167569.  https://doi.org/10.1016/j.jmb.2022.167569
    56 2023 Matthew N. O’Brien Laramy, Suman Luthra, Matthew F. Brown, Derek W. Bartlett. Delivering on the promise of protein degraders, Nature Reviews Drug Discovery. 2023; 22: 410.  https://doi.org/10.1038/s41573-023-00652-2
    57 2021 José A. Villegas, Tasneem M. Vaid, Michael E. Johnson, Terry W. Moore. 2021;   https://doi.org/10.1101/2021.08.31.458424
    58 2023 Yu Chen, Wen Li, Song Kwon, Yixin Wang, Zhaoting Li, Quanyin Hu. Small-Molecule Ferritin Degrader as a Pyroptosis Inducer, Journal of the American Chemical Society. 2023; 145: 9815.  https://doi.org/10.1021/jacs.3c01852
    59 2023 José A. Villegas, Tasneem M. Vaid, Michael E. Johnson, Terry W. Moore. Mapping the energy landscape of PROTAC-mediated protein-protein interactions, Computational and Structural Biotechnology Journal. 2023; 21: 1885.  https://doi.org/10.1016/j.csbj.2023.02.049
    60 2021 Gabriel LaPlante, Wei Zhang. Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors, Cancers. 2021; 13: 3079.  https://doi.org/10.3390/cancers13123079
    61 2023 Jeremy M. Kelm, Deepti S. Pandey, Evan Malin, Hussein Kansou, Sahil Arora, Raj Kumar, Navnath S. Gavande. PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy, Molecular Cancer. 2023; 22: 62.  https://doi.org/10.1186/s12943-022-01707-5
    62 2023 Ammar Usman Danazumi, Ibtida Tabassum Ishmam, Salisu Idris, Matylda Anna Izert, Emmanuel Oluwadare Balogun, Maria Wiktoria Górna. Targeted protein degradation might present a novel therapeutic approach in the fight against African trypanosomiasis, European Journal of Pharmaceutical Sciences. 2023; 186: 106451106451.  https://doi.org/10.1016/j.ejps.2023.106451
    63 2022 Tian Niu, Kailin Li, Li Jiang, Zhesheng Zhou, Ju Hong, Xuankun Chen, Xiaowu Dong, Qiaojun He, Ji Cao, Bo Yang, Cheng-Liang Zhu. Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor, European Journal of Medicinal Chemistry. 2022; 228: 114012114012.  https://doi.org/10.1016/j.ejmech.2021.114012
    64 2022 Jasmine M. Cross, Megan E. Coulson, Joshua P. Smalley, Wiktoria A. Pytel, Ozair Ismail, Justin S. Trory, Shaun M. Cowley, James T. Hodgkinson. A ‘click’ chemistry approach to novel entinostat (MS-275) based class I histone deacetylase proteolysis targeting chimeras, RSC Medicinal Chemistry. 2022; 13: 1634.  https://doi.org/10.1039/D2MD00199C
    65 2022 Samantha M. Meyer, Toru Tanaka, Patrick R. A. Zanon, Jared T. Baisden, Daniel Abegg, Xueyi Yang, Yoshihiro Akahori, Zainab Alshakarchi, Michael D. Cameron, Alexander Adibekian, Matthew D. Disney. DNA-Encoded Library Screening To Inform Design of a Ribonuclease Targeting Chimera (RiboTAC), Journal of the American Chemical Society. 2022; 144: 21096.  https://doi.org/10.1021/jacs.2c07217
    66 2022 Charles E. Hendrick, Jeff R. Jorgensen, Charu Chaudhry, Iulia I. Strambeanu, Jean-Francois Brazeau, Jamie Schiffer, Zhicai Shi, Jennifer D. Venable, Scott E. Wolkenberg. Direct-to-Biology Accelerates PROTAC Synthesis and the Evaluation of Linker Effects on Permeability and Degradation, ACS Medicinal Chemistry Letters. 2022; 13: 1182.  https://doi.org/10.1021/acsmedchemlett.2c00124
    67 2022 Lisbeth R. Kjølbye, Gilberto P. Pereira, Alessio Bartocci, Martina Pannuzzo, Simone Albani, Alessandro Marchetto, Brian Jiménez-García, Juliette Martin, Giulia Rossetti, Marco Cecchini, Sangwook Wu, Luca Monticelli, Paulo C. T. Souza. Towards design of drugs and delivery systems with the Martini coarse-grained model, QRB Discovery. 2022; 3: e19.  https://doi.org/10.1017/qrd.2022.16
    68 2023 Poornachandra Yedla, Ahmed O. Babalghith, Vindhya Vasini Andra, Riyaz Syed. PROTACs in the Management of Prostate Cancer, Molecules. 2023; 28: 3698.  https://doi.org/10.3390/molecules28093698
    69 2023 Qian-Qian Zhou, Hai-Tao Xiao, Fan Yang, Yong-Dan Wang, Ping Li, Zu-Guo Zheng. Advancing targeted protein degradation for metabolic diseases therapy, Pharmacological Research. 2023; 188: 106627106627.  https://doi.org/10.1016/j.phrs.2022.106627
    70 2023 Hai‐Jun Liu, Wei Chen, Gongwei Wu, Jun Zhou, Chuang Liu, Zhongmin Tang, Xiangang Huang, Jingjing Gao, Yufen Xiao, Na Kong, Nitin Joshi, Yihai Cao, Reza Abdi, Wei Tao. Glutathione‐Scavenging Nanoparticle‐Mediated PROTACs Delivery for Targeted Protein Degradation and Amplified Antitumor Effects, Advanced Science. 2023; 10: 2207439.  https://doi.org/10.1002/advs.202207439
    71 2021 Kunal Nepali, Jing-Ping Liou. Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends, Journal of Biomedical Science. 2021; 28: 27.  https://doi.org/10.1186/s12929-021-00721-x
    72 2022 Xingui Liu, Alexia F. Kalogeropulou, Sofia Domingos, Nikolai Makukhin, Raja S. Nirujogi, Francois Singh, Natalia Shpiro, Anton Saalfrank, Esther Sammler, Ian G. Ganley, Rui Moreira, Dario R. Alessi, Alessio Ciulli. Discovery of XL01126: A Potent, Fast, Cooperative, Selective, Orally Bioavailable, and Blood–Brain Barrier Penetrant PROTAC Degrader of Leucine-Rich Repeat Kinase 2, Journal of the American Chemical Society. 2022; 144: 16930.  https://doi.org/10.1021/jacs.2c05499
    73 2023 Song Chen, Zhendong Chen, Lixue Lu, Yunpeng Zhao, Ronghui Zhou, Qiong Xie, Yongzhi Shu, Jun Lin, Xufen Yu, Yonghui Wang. Discovery of novel BTK PROTACs with improved metabolic stability via linker rigidification strategy, European Journal of Medicinal Chemistry. 2023; 255: 115403115403.  https://doi.org/10.1016/j.ejmech.2023.115403
    74 2023 Yang Zhou, Shujing Xu, Nerea López-Carrobles, Dang Ding, Xinyong Liu, Luis Menéndez-Arias, Peng Zhan. Recent advances in the molecular design and applications of proteolysis targeting chimera-based multi-specific antiviral modality, Acta Materia Medica. 2023; 2:   https://doi.org/10.15212/AMM-2023-0019
    75 2023 Satoshi Yamanaka, Hirotake Furihata, Yuta Yanagihara, Akihito Taya, Takato Nagasaka, Mai Usui, Koya Nagaoka, Yuki Shoya, Kohei Nishino, Shuhei Yoshida, Hidetaka Kosako, Masaru Tanokura, Takuya Miyakawa, Yuuki Imai, Norio Shibata, Tatsuya Sawasaki. Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation, Nature Communications. 2023; 14: 4683.  https://doi.org/10.1038/s41467-023-40385-9
    76 2023 Chelsi M. Almodóvar‐Rivera, Zhen Zhang, Jingyao Li, Haibo Xie, Yu Zhao, Le Guo, Marissa G. Mannhardt, Weiping Tang. A Modular Chemistry Platform for the Development of a Cereblon E3 Ligase‐Based Partial PROTAC Library, ChemBioChem. 2023; e202300482.  https://doi.org/10.1002/cbic.202300482
    77 2023 Toshihiko Tashima, Proteolysis-Targeting Chimera (PROTAC) Delivery into the Brain across the Blood-Brain Barrier, Antibodies. 2023; 12: 43.  https://doi.org/10.3390/antib12030043
    78 2023 Rajni Bala, Rakesh Kumar Sindhu, Reecha Madaan, Shantanu Kumar Yadav. PROTAC: A Novel Drug Delivery Technology for Targeting Proteins in Cancer Cells, Current Drug Discovery Technologies. 2023; 20: e311022210504.  https://doi.org/10.2174/1570163820666221031124612
    79 2021 Chiara Tarantelli, Eleonora Cannas, Hillarie Ekeh, Carmelo Moscatello, Eugenio Gaudio, Luciano Cascione, Sara Napoli, Cesare Rech, Andrea Testa, Chiara Maniaci, Andrea Rinaldi, Emanuele Zucca, Anastasios Stathis, Alessio Ciulli, Francesco Bertoni. The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type, Exploration of Targeted Anti-tumor Therapy. 2021; 2: 586.  https://doi.org/10.37349/etat.2021.00065
    80 2023 Daniel H. O’ Donovan, Claudia De Fusco, Lara Kuhnke, Andreas Reichel. Trends in Molecular Properties, Bioavailability, and Permeability across the Bayer Compound Collection, Journal of Medicinal Chemistry. 2023; 66: 2347.  https://doi.org/10.1021/acs.jmedchem.2c01577
    81 2023 Mayuri P Kannan, Sarojini Sreeraman, Chaitanya S Somala, Raja BS Kushwah, Saravanan K Mani, Vickram Sundaram, Anand Thirunavukarasou. Advancement of targeted protein degradation strategies as therapeutics for undruggable disease targets, Future Medicinal Chemistry. 2023; 15: 867.  https://doi.org/10.4155/fmc-2023-0072
    82 2021 Ying Wang, Isabella Haight, Rishi Gupta, Anil Vasudevan. What is in Our Kit? An Analysis of Building Blocks Used in Medicinal Chemistry Parallel Libraries, Journal of Medicinal Chemistry. 2021; 64: 17115.  https://doi.org/10.1021/acs.jmedchem.1c01139
    83 2023 Chuang Li, Peng Zhang, Gaojie Chang, Mingyue Pan, Fengke Lu, Jiahao Huang, Yanzhi Wang, Qingyan Zhao, Bingxia Sun, Yuting Cui, Feng Sang. Proteolysis Targeting Chimeras (PROTACs) Based on Imatinib Induced Degradation of BCR‐ABL in K562 Cells, ChemistrySelect. 2023; 8: e202300095.  https://doi.org/10.1002/slct.202300095
    84 2023 Keisuke Hamada, Ten Hashimoto, Rinoka Iwashita, Yuji Yamada, Yamato Kikkawa, Motoyoshi Nomizu. Development of a bispecific DNA-aptamer-based lysosome-targeting chimera for HER2 protein degradation, Cell Reports Physical Science. 2023; 4: 101296101296.  https://doi.org/10.1016/j.xcrp.2023.101296
    85 2023 Deep Rohan Chatterjee, Saumya Kapoor, Meenakshi Jain, Rudradip Das, Moumita Ghosh Chowdhury, Amit Shard. PROTACting the kinome with covalent warheads, Drug Discovery Today. 2023; 28: 103417103417.  https://doi.org/10.1016/j.drudis.2022.103417
    86 2023 Ki Bum Hong, Hongchan An. Degrader–Antibody Conjugates: Emerging New Modality, Journal of Medicinal Chemistry. 2023; 66: 140.  https://doi.org/10.1021/acs.jmedchem.2c01791
    87 2023 Hanqiao Xu, Takashi Kurohara, Nobumichi Ohoka, Genichiro Tsuji, Takao Inoue, Mikihiko Naito, Yosuke Demizu. Development of versatile solid-phase methods for syntheses of PROTACs with diverse E3 ligands, Bioorganic & Medicinal Chemistry. 2023; 86: 117293117293.  https://doi.org/10.1016/j.bmc.2023.117293
    88 2023 Martin P. Schwalm, Andreas Krämer, Anja Dölle, Janik Weckesser, Xufen Yu, Jian Jin, Krishna Saxena, Stefan Knapp. Tracking the PROTAC degradation pathway in living cells highlights the importance of ternary complex measurement for PROTAC optimization, Cell Chemical Biology. 2023; 30: 753.  https://doi.org/10.1016/j.chembiol.2023.06.002
    89 2023 Ryan P. Wurz, Huan Rui, Ken Dellamaggiore, Sudipa Ghimire-Rijal, Kaylee Choi, Kate Smither, Albert Amegadzie, Ning Chen, Xiaofen Li, Abhisek Banerjee, Qing Chen, Dane Mohl, Amit Vaish. Affinity and cooperativity modulate ternary complex formation to drive targeted protein degradation, Nature Communications. 2023; 14: 4177.  https://doi.org/10.1038/s41467-023-39904-5
    90 2022 Alberto Juan, María del Mar Noblejas-López, María Arenas-Moreira, Carlos Alonso-Moreno, Alberto Ocaña. Options to Improve the Action of PROTACs in Cancer: Development of Controlled Delivery Nanoparticles, Frontiers in Cell and Developmental Biology. 2022; 9: 805336.  https://doi.org/10.3389/fcell.2021.805336
    91 2022 Fabian Fischer, Leandro A Alves Avelar, Laoise Murray, Thomas Kurz. Designing HDAC-PROTACs: lessons learned so far, Future Medicinal Chemistry. 2022; 14: 143.  https://doi.org/10.4155/fmc-2021-0206
    92 2023 Francesco Di Palma, Carlo Abate, Sergio Decherchi, Andrea Cavalli. Ligandability and druggability assessment via machine learning, WIREs Computational Molecular Science. 2023; 13: e1676.  https://doi.org/10.1002/wcms.1676
    93 2023 Yuen Lam Dora Ng, Aleša Bricelj, Jacqueline A. Jansen, Arunima Murgai, Kirsten Peter, Katherine A. Donovan, Michael Gütschow, Jan Krönke, Christian Steinebach, Izidor Sosič. Heterobifunctional Ligase Recruiters Enable pan-Degradation of Inhibitor of Apoptosis Proteins, Journal of Medicinal Chemistry. 2023; 66: 4703.  https://doi.org/10.1021/acs.jmedchem.2c01817
    94 2022 Yiqing Zhang, Xiaoxia Liu, Daniel J Klionsky, Boxun Lu, Qing Zhong. Manipulating autophagic degradation in human diseases: from mechanisms to interventions, Life Medicine. 2022; 1: 120.  https://doi.org/10.1093/lifemedi/lnac043
    95 2023 Melissa Guardigni, Letizia Pruccoli, Alan Santini, Angela De Simone, Matteo Bersani, Francesca Spyrakis, Flavia Frabetti, Elisa Uliassi, Vincenza Andrisano, Barbara Pagliarani, Paula Fernández-Gómez, Valle Palomo, Maria Laura Bolognesi, Andrea Tarozzi, Andrea Milelli. PROTAC-Induced Glycogen Synthase Kinase 3β Degradation as a Potential Therapeutic Strategy for Alzheimer’s Disease, ACS Chemical Neuroscience. 2023; 14: 1963.  https://doi.org/10.1021/acschemneuro.3c00096
    96 2023 Liwen Hua, Danni Wang, Keran Wang, Yuxuan Wang, Jinying Gu, Qiuyue Zhang, Qidong You, Lei Wang. Design of Tracers in Fluorescence Polarization Assay for Extensive Application in Small Molecule Drug Discovery, Journal of Medicinal Chemistry. 2023; 66: 10934.  https://doi.org/10.1021/acs.jmedchem.3c00881
    97 2023 Chunlan Pu, Shirui Wang, Lei Liu, Zhonghui Feng, Hongjia Zhang, Qianyuan Gong, Yueshan Sun, Yuanbiao Guo, Rui Li. Current strategies for improving limitations of proteolysis targeting chimeras, Chinese Chemical Letters. 2023; 34: 107927107927.  https://doi.org/10.1016/j.cclet.2022.107927
    98 2022 Marine C. Aublette, Tom A. Harrison, Elizabeth J. Thorpe, Morgan S. Gadd. Selective Wee1 degradation by PROTAC degraders recruiting VHL and CRBN E3 ubiquitin ligases, Bioorganic & Medicinal Chemistry Letters. 2022; 64: 128636128636.  https://doi.org/10.1016/j.bmcl.2022.128636
    99 2023 Nikol A. Zografou-Barredo, Alex J. Hallatt, Jennyfer Goujon-Ricci, Céline Cano. A beginner’s guide to current synthetic linker strategies towards VHL-recruiting PROTACs, Bioorganic & Medicinal Chemistry. 2023; 88-89: 117334117334.  https://doi.org/10.1016/j.bmc.2023.117334